- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01919827
Study of Autologous Mesenchymal Stem Cells to Treat Idiopathic Pulmonary Fibrosis (CMM/FPI)
Treatment of Idiopathic Pulmonary Fibrosis With Bone Marrow Derived Mesenchymal Stem Cells
Clinical Trial Phase I, open, multicentric, non randomized, study with escalating doses, to evaluate the safety and feasibility of treatment with mesenchymal stem cells in patients with diagnosis of idiopathic pulmonary fibrosis.
Primary endpoint: The aim is to evaluate the safety and feasibility of the endobronchial administration of mesenchymal autolog stem cells derived from bone marrow (BM-MSC)in patients with mild-to-moderate idiopathic pulmonary fibrosis.
Secondary endpoint:Assess the possible effect of the infusion of BM-MSC in stopping the fall of pulmonary function in patients with mild-to-moderate idiopathic pulmonary fibrosis.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Salamanca, Spain
- Servicio de Neumología. Hospital Universitario de Salamanaca
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008 Pamplona
- Servicio de Neumología, Clínica Universidad de Navarra
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA:
- Capacity for signing informing consent and express the willing to fulfill all the requirements of the study protocol during the study.
- The patients should be, in the researcher opinion, capable to fulfill all the requirements of the trial.
- Male or female patients, 30 to 80 years old, inclusive.
Diagnosis of idiopathic pulmonary fibrosis according to the following criteria, based on the ATS/ERS Guidelines:
- Definite or probable usual interstitial pneumonia confirmed by surgical lung biopsy.
- In the absence of surgical lung biopsy, all the following:
i. High resolution CT (HRCT) showing definite findings for idiopathic pulmonary fibrosis (FPI): bibasal reticular opacities with minimal ground glass opacities.
ii. Absence of other known causes of FPI including toxicity from drugs, environmental exposure or connective tissue diseases.
iii. Pulmonary function tests showing ventilatory restrictive pattern and/or impaired gas exchange (FVC and/or DLCO <90% of predicted)
- FVC ≥ 50% of predicted value with ratio of FEV1 to FVC ≥ 0.70.
- DLco (corrected for hemoglobin) ≥ 35% predicted value.
- Capability of performing a 6 minutes walk test at the time of inclusion.
EXCLUSION CRITERIA:
Any of the following:
- Current pregnancy or lactation.
- Findings that are diagnostic of an interstitial pneumonia or restrictive respiratory disease condition other than UIP.
- Obstructive pulmonary disease defined by FEV1/FVC < 0,7 or significant emphysema on HRCT.
- Evidence of sustained improvement in FPI defined by improvement of respiratory function tests before inclusion, observed in >=2 test over the year prior to inclusion.
- Active or recent respiratory infection (less than 60 days before inclusion) or history of frequent exacerbations of IPF from an infectious cause (more than 2/year over the last 2 years)
- Hospitalization in the 60 days prior to inclusion due to acute exacerbation of IPF.
- Chronic cardiac failure (functional class NYHA III/IV) or left ventricular ejection fraction < 25%.
- Chronically receiving corticosteroid more than 10 mg of prednisone or equivalent, immunosuppressors or antifibrotic agents, including pirfenidone, D-penicillamine, colchicine, ciclosporin A, TNF-alpha antagonists, imatinib, IFN-gamma, azathioprine, cyclophosphamide, within the 30 days prior to inclusion.
- The patient requires hemodialysis, peritoneal dialysis or hemofiltration.
- History of malignancy, with the exception of skin squamous or basocellular carcinoma or cervix in situ carcinoma treated successfully.
- History of ethanol abuse within the year prior to inclusion
- The patient is participating in a clinical trial which includes other drugs or research products within the 28 days prior to baseline assessment.
- Comorbidities limiting life expectancy to less than 12 months from the baseline assessment.
- Medical or psychiatric condition serious or active which might interfere with the treatment of study, assessment or protocol fulfillment.
- Positive test for HBsAg, HCV antibody, syphilis screening essays, or HIV antibody at screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MSC endobronchial infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with adverse side effects.
Time Frame: Up to 12 months
|
Number of participants with adverse side effects, and according to the level of severity:
|
Up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of the infusion of mesenchymal stem cells in stopping the fall in pulmonary function in patients with mild to moderate IPF
Time Frame: Up to 12 months
|
Measures of efficacy:
|
Up to 12 months
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CMM/FPI
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Pulmonary Fibrosis
-
St. Antonius HospitalZonMw: The Netherlands Organisation for Health Research and Development; Boeringer...RecruitingPulmonary Fibrosis Idiopathic FamilialNetherlands
-
Wake Forest University Health SciencesMayo Clinic; The University of Texas Health Science Center at San AntonioCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Sheba Medical CenterUnknownIDIOPATHIC PULMONARY FIBROSISIsrael
-
Theravance BiopharmaTerminatedIdiopathic Pulmonary Fibrosis (IPF)United Kingdom
-
University of California, San FranciscoCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
BiogenCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Liminal BioSciences Ltd.CompletedIdiopathic Pulmonary Fibrosis (IPF)Canada
-
Bristol-Myers SquibbCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Angion Biomedica CorpNot yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
-
Xfibra, Inc.Not yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
Clinical Trials on Endobronchial infusion of adult mesenchymal stem cells
-
National Research Center for Hematology, RussiaUnknownRelapse | Graft-versus-host DiseaseRussian Federation
-
University of LiegeCompletedHematological MalignanciesBelgium
-
Stemedica Cell Technologies, Inc.University of California, San Diego; Mercy Gilbert Medical Center at AZ; Chandler... and other collaboratorsCompletedIschemic StrokeUnited States
-
National Yang Ming UniversityCompleted
-
Leiden University Medical CenterCompleted
-
UPECLIN HC FM Botucatu UnespLaboratório de Genética Humana e Terapia Celular, Unesp - Assis; Instituto...CompletedChronic Obstructive Pulmonary Disease | Pulmonary EmphysemaBrazil
-
Universidad de la SabanaFundación Neumologica Colombiana; Stem Medicina Regenerativa; Innocell SASAvailablePulmonary Fibrosis | Pulmonary Hypertension | Systemic Sclerosis PulmonaryColombia
-
Mayo ClinicCompletedAtherosclerotic Renal Artery Stenosis | Ischemic Nephropathy | Renovascular HypertensionUnited States
-
EHL Bio Co., Ltd.CompletedAtopic DermatitisKorea, Republic of
-
Instituto de Investigación Hospital Universitario...Hospital Universitario La PazCompletedNonrevascularizable Critical Ischemia of the Lower LimbsSpain